Introduction
Defective insulin signalling in its target tissues is a major feature of the pathophysiology of human obesity and non-insulin-dependent diabetes mellitus (1-3). While major advances have February 1995. recently been made in our understanding of the central role for reversible tyrosine phosphorylation of the insulin receptor and its cellular substrate proteins in the mechanism of insulin action (4), we still do not have a clear picture of how these events are regulated, or of molecular defects that may lead to the insulin resistance observed in disease states.
Several recent studies have provided evidence that proteintyrosine phosphatases (PTPases)' have an integral role in the regulation of insulin signal transduction (5) . PTPases can dephosphorylate and attenuate the active (autophosphorylated) form of the insulin receptor tyrosine kinase. In addition, PTPases may modulate post-receptor signalling by dephosphorylating the phosphotyrosyl form of cellular substrate proteins for the insulin receptor such as IRS-1 and Shc, which signal to downstream enzymes as "docking" proteins that bind and activate a number of src-homology 2 (SH2) domain-containing signalling proteins (4) . Thus, the opposing effects of phosphorylation by the insulin receptor kinase and dephosphorylation by cellular PTPases will regulate the state of tyrosine phosphorylation of signalling proteins in the insulin action pathway.
From the expanding superfamily of protein-tyrosine phosphatases (6) , work in our laboratory and others has implicated the tandem-domain transmembrane enzyme LAR (7) and the intracellular, single domain PTPases 1B (8, 9) and SH-PTP2/ syp (also termed PTP1D or PTP2C) (10, 11) , as candidate PTPases for the regulation of the insulin action pathway. In addition to being relatively prominent PTPases in adipose tissue and other insulin-sensitive tissues, these enzymes have catalytic activity towards the insulin receptor or its substrate proteins in studies done both in vitro and in vivo (5, 12) . Of these PTPases, we have been particularly interested in the transmembrane PTPase LAR (7) since it is expressed in insulin-sensitive liver, muscle, and adipose tissue (5) , it is localized to the membrane fraction of the cell where the insulin receptor is rapidly dephosphorylated (13, 14) , and it has a catalytic preference for the regulatory phosphotyrosines in the insulin receptor kinase domain (15) . Furthermore, reduction of LAR enzyme mass by expression of antisense mRNA in hepatoma cells markedly enhances insulin receptor autophosphorylation and insulin-stimulated phosphatidylinositol 3 '-kinase activity (44) . These (20) . In both cases, the antibodies were affinity-purified using Affi-Gel (Bio-Rad) columns containing immobilized purified LAR cytoplasmic domain (21 
Resufts
Subcutaneous adipose tissue samples were obtained during elective surgery from 6 normal weight and 6 obese (BMI > 30) individuals. None of the subjects had overt diabetes mellitus as manifested by hyperglycemia during pre-or post-operative testing, and none were taking oral hypoglycemic medications or insulin. The two groups were not significantly different in age or in their composition by gender or race (Table I) .
Homogenates were prepared from the adipose tissue specimens and samples were tested for PTPase activity towards the insulin receptor. Since the PTPase assay was performed with matching amounts of protein from each homogenate sample, the results reflect the specific activity of the PTPase towards the autophosphorylated insulin receptor (Table  II) . PTPaselB protein levels were only slightly increased on average by 1.22-fold, albeit with statistical significance. SH-PTP2, which has in recent studies been shown to be a positive mediator of insulin signalling and might have been postulated C 1 2 3 4 5 6 7 8 9 10 11 12 -IRKD to be reduced in insulin-resistant states (22, 23) , was actually moderately increased by 1.45-fold in the adipose tissue homogenates from the obese individuals.
Analysis of LAR protein mass by immunoblotting showed a dramatic increase in the obese subjects compared to the normal weight individuals (Fig. 3) . Quantitation of the phosphorimage density from all of the patients in the two groups revealed a highly significant mean increase of 2.03-fold in the adipose tissue of the obese subjects (Table II) . In addition, linear regression analysis of the individual data points also showed a strong relationship between the BMI and the amount of LAR enzyme per mg of protein in the tissue homogenates (Fig. 4) (Fig. 5) . When LAR protein was depleted from the adipose tissue samples from the obese subjects, the increased PTPase activity in the tissue supernatants was essentially normalized with no statistically significant difference between immunodepleted samples from the obese subjects compared with the immunodepleted lean control samples (Fig. 5 
Discussion
The relationship between increasing body adiposity and defects in insulin action in its target tissues is well-characterized but poorly understood at the cellular level (24) . In normal volunteers, increasing body mass over a threshold value is highly correlated with decreasing sensitivity to insulin (25, 26) . In individuals with a genetic predisposition, the insulin resistance associated with obesity can lead to impaired glucose tolerance or frank diabetes. The impact of obesity and insulin resistance on several interrelated risk factors, including the circulating insulin level, hypertension, and dyslipidemias has heightened awareness of this common and important constellation of findings for cardiovascular disease (27) . The site of cellular insulin resistance in adipose tissue in human obesity has not been clearly identified, although defects in both insulin binding capacity and in post-binding signalling have been reported (2, 24, 28, 29) . In one report, partially purified receptors from adipocytes of obese subjects had normal insulin receptor kinase activity compared with lean control subjects (30 (36) (37) (38) (39) and in aging (40) .
The present study provides the first evidence for increased PTPase activity towards the insulin receptor in adipose tissue from obese human subjects, lending further support to the hypothesis that aberrant expression of PTPases may be an integral part of the pathogenesis of insulin resistance with increasing body mass in this tissue. Previous studies in human subjects, performed with skeletal muscle biopsy material from insulinresistant but nondiabetic Pima Native American subjects showed that basal PTPase activity towards derivatized lysozyme in the particulate fraction of muscle was 33% higher than in insulin-sensitive controls (41) . In further studies, insulin infusion in vivo produced a rapid 25% suppression of soluble PTPase activity in muscle of insulin-sensitive subjects, but this response was severely impaired in the insulin-resistant subjects. In contrast, a related study by Kusari et al. (42) , performed with a different patient population, showed that the skeletal muscle particulate fraction PTPase activity against phosphopeptide substrates was reduced by 21-22% in obese nondiabetic and non-insulin-dependent diabetic subjects. Furthermore, the basal particulate fraction PTPase activity was positively correlated with the insulin-stimulated glucose disposal rate and weight loss resulted in a significant increase in both the skeletal muscle particulate fraction PTPase activity and in the insulinstimulated glucose disposal rate (42) . In relation to the present study, it is not clear how the tissue dephosphorylating activity towards a synthetic phosphopeptide substrate might compare to the dephosphorylation of a native substrate from the insulin signalling pathway, such as IRS-I or the insulin receptor itself. The main difference between the studies in skeletal muscle and the present work is in the tissue examined, and the contrasting results suggest the possibility that different mechanisms might underlie the observed defects in insulin signalling in muscle versus adipose tissue. Additional studies in human skeletal muscle with the intact insulin receptor as substrate are warranted to explore whether there might be substrate-specific alterations in PTPase activity in insulin-resistant subjects.
In related work, we recently assessed PTPase enzyme activities in subcellular fractions of skeletal muscle in lean (+/?), obese (falfa) Zucker and diabetic (ZDF/Drt-fa/fa) Zucker rats, a well-characterized rodent model of genetically determined insulin-resistant obesity and diabetes (43) . In both the obese and diabetic animals, the muscle particulate fraction PTPase activity was significantly increased by 100-110% towards the autophosphorylated insulin receptor kinase domain. This enhanced PTPase activity was associated with increases ranging from 40-70% in the specific immunoreactivity of LAR, PTPaselB, and SH-PTP2 in the particulate fraction of the affected animals (43) ( 13, 14) , and we have demonstrated in biochemical studies in vitro that its cytoplasmic domain has a catalytic preference for the regulatory phosphotyrosines in the insulin receptor kinase domain (15) . In further studies, expression of LAR antisense mRNA in hepatoma cells to reduce LAR mass, insulin receptor autophosphorylation was increased to 150% of control and insulin-stimulated phosphatidylinositol 3'-kinase activity was further amplified to 300% over the level observed in cells transfected with the null expression vector (44) . Taken together, these studies provide strong evidence that LAR is a physiological modulator of insulin signalling.
A small increase in the abundance of PTPaselB was also noted in the adipose tissue from obese individuals. PTPaselB is a widely expressed enzyme that was first identified as a prominent PTPase in placenta (45). Recently, cell transfection studies have suggested that this PTPase has a potential role in the regulation of tyrosine phosphorylation catalyzed by insulin and insulin like growth factor-I receptors as well as receptors for platelet derived growth factor and epidermal growth factor (46) . In the human studies by Kusari et al. (42) , the reduced PTPase activity towards phosphopeptide substrates was associated with a mean decrease of 38% in PTPaselB protein abundance in the diabetic subjects, although substantial variation was observed in both control and diabetic groups. Clearly, further work is needed to assess tissue differences that might exist in the regulation of the abundance of various candidate insulin receptor PTPase enzymes. In addition, the relationship between the abundance of PTPaselB (and other candidate PTPases) and the overall tissue PTPase activity that is measured in subcellular fractions needs to be addressed for skeletal muscle, as we have done for adipose tissue in the case of LAR.
The potential role of SH-PTP2 in insulin signalling is also an important question that is under intensive study in several laboratories. SH-PTP2 associates with tyrosine-phosphorylated IRS-1 by its SH2 domains (47) (48) (49) . In recombinant in vitro systems, SH-PTP2 has also been shown to associate with the insulin receptor and can be phosphorylated by the insulin receptor kinase (23, (50) (51) (52) . However, several studies in vivo have failed to demonstrate either a direct interaction between SH-PTP2 and insulin receptors or any effects of over-expression of the native, catalytically active SH-PTP2 enzyme on the phosphorylation state of the insulin receptor or on insulin signalling in intact cells (22, 53, 54) . Recent evidence suggests that SH-PTP2 may have a positive role in growth factor signalling in mammalian cells. Single-cell microinjection of SH-PTP2 antibody, a glutathione-S-transferase fusion construct with the SH2 domains of SH-PTP2, or IRS-i-derived phosphopeptides that bind to the SH2 domains of SH-PTP2 blocks insulin-stimulated mitogenic signalling (23) , and inducible expression of a catalytically inactive (Cys459 -+ Ser) SH-PTP2 mutant in NIH 3T3 fibroblasts over-expressing the insulin receptor blocks insulinstimulated mitogenesis as well as the phosphorylation and activation of MAP kinase by insulin (22) . Thus, although there is an increase in SH-PTP2 abundance in adipose tissue from the obese subjects, it is uncertain how this may impact on insulin signalling in this tissue, whether enhancing insulin action or acting in concert with LAR in the insulin resistance that is evident in the obese state.
In summary, these studies provide evidence that supports the hypothesis that increased PTPase activity towards the native insulin receptor is associated with insulin resistance in adipose tissue from obese subjects. Furthermore, a specific candidate PTPase for the insulin action pathway, LAR, has been shown to be increased in obesity and accounts for the observed increase in insulin receptor dephosphorylating activity in the tissue homogenates. Further studies will help characterize the reversibility of this effect in adipose tissue and whether a more generalized increase in LAR enzyme abundance occurs in other insulin sensitive tissues, including liver and skeletal muscle. Finally, these studies raise the possibility that LAR may be involved not only in the insulin resistance of obesity but also more generally in tissue insulin resistance associated with genetically determined diabetes or in more common forms of insulin resistance with increased cardiovascular risk factors.
